Establishing a Biomarker-Driven Approach to Guide Patient Selection for pre|CISION® Peptide-Drug Conjugates Using Tumour Targeting/Release & Payload Sensitivity Biomarkers
- Avacta’s pre|CISION® peptide-drug conjugates comprise a peptide moiety bound to a cytotoxic payload by a linker that is specifically cleaved by FAP, a protease selectively overexpressed in the tumour microenvironment of many solid tumours
- AVA6000 (FAP-activated doxorobucin) is completing Phase 1b and has shown promising results, whilst AVA6103 (FAPactivated exatecan) is due to enter the clinic in Q1 2026
- A pan-cancer evaluation of FAP expression across multiple datasets supports the identification of tumour types most likely to benefit from FAP-activated pre|CISION® therapeutics
- Pan-cancer evaluation of DNA-damage response pathways enables identification of patient subsets most likely to benefit from payload-driven therapeutic activity